Financial incentives and feedback coincide with sustained improvement in breast RT structure naming
Across 12,853 breast RT patients, TG-263 naming compliance increased and remained high after financial incentives were discontinued.
Across 12,853 breast RT patients, TG-263 naming compliance increased and remained high after financial incentives were discontinued.
Uncertainty scoring detected metal-related distribution shifts with AUC up to 0.89 and identified cases with reduced segmentation accuracy.
Direct AI-generated IMPT spot weights achieved over 98% whole-body gamma agreement for prostate and brain plans, but lung target coverage deteriorated.
New ARS consensus supports 60 Gy in 15 fractions for selected peripheral tumors but recommends more conservative schedules near critical structures.
Only 22.6% of surveyed radiation oncologists routinely offered both hippocampal avoidance and memantine, while 46.8% offered neither as standard options.
ProSpare reduced anorectal dose and showed numerically lower grade ≥1 bowel symptoms, with its primary two-year outcome still pending.
Consolidative thoracic RT was associated with median survival of 27.0 versus 15.5 months, but major treatment-selection imbalances limit interpretation.
Hypofractionated postmastectomy RT met noninferiority criteria for reconstruction complications, with 24-month rates of 12.3% versus 10.2% after conventional RT.
Whole-liver RT to 7 Gy followed by PD-1 blockade produced four responses in six patients with refractory diffuse hepatic metastases.
A dual-view AI model predicted grade ≥2 breast radiation dermatitis with AUC 0.91 overall and approximately 0.80 by week three.
In 40 breast and chest wall plans, DynamicArc improved coverage and robustness in challenging anatomies but increased thyroid dose and hotspots.
In 77 high-risk prostate patients, five-fraction adaptive pelvic SBRT produced 6.9% late grade ≥2 GU and 9.7% GI toxicity.
In 72 matched pairs, initial local therapy without systemic treatment was associated with 73.0% versus 58.6% five-year survival, without improved PFS.
In 142 patients with limited-stage SCLC, CBCT-reconstructed dose improved pneumonitis and esophagitis prediction compared with planned dose, but discrimination remained modest.
An expert training framework defines the clinical, dosimetric, procedural and radiation safety competencies required for independent ocular plaque brachytherapy practice.